SynthesisJournal of immunology research2018
Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis.
Synthesis in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Immune checkpoint inhibitors-induced pancreatitis: a systematic review and real-world pharmacovigilance analysis.Frontiers in pharmacology · 2025Pooled it
- Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events.Journal for immunotherapy of cancer · 2024Pooled it
- Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.BMC cancer · 2019Pooled it
- Article
- [Diagnostics and therapy of gastroenterological side effects of immune checkpoint inhibitor therapy].Magyar onkologia · 2025Review
- Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Investigating Immune Checkpoint Inhibitor-Induced Pancreatic Injury: When to Discontinue Cancer Therapy.Metabolites · 2025Review
- Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis.Investigational new drugs · 2025Article
- Clinical characteristics and prognosis of pancreatitis associated with immune checkpoint inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Endoscopic Ultrasound With Fine Needle Biopsy Confirming a Diagnosis of Immune Checkpoint Inhibitor-Related Type 3 Autoimmune Pancreatitis.Case reports in gastrointestinal medicine · 2025Article
- Risk factors and long-term prognostic impact of immune related pancreatic injury in patients receiving immune checkpoint inhibitors.Frontiers in immunology · 2025Article
- Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.Journal of gastroenterology · 2024Article
- Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2024Review
- Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study.Immunotherapy · 2024Article
- A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2023Review
- Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.Cancer immunology, immunotherapy : CII · 2023Article
- Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis.ACG case reports journal · 2023Article
- Rituximab in steroid-refractory immune-related pancreatitis: a case report.Frontiers in oncology · 2023Article
- Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a systematic review and meta-analysis to determine the risk of immune-related pancreatitis associated with the treatment by immune checkpoint inhibitors (ICIs) for solid tumors. Eligible studies were selected from multiple databases including phase II/III randomized controlled trials (RCTs) with ICIs in solid tumor patients. The data were analyzed with Stata version 12.0 software. After excluding ineligible studies, a total of 15 clinical trials were considered eligible for the meta-analysis, which included 9099 patients. Compared with chemotherapy or placebo, the risk ratio (RR) for all-grade lipase elevation after CTLA-4 inhibitor treatment was 1.05 (95% confidence interval (CI): 1.01-2.24,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.